fashion -WSS

fashion

author：entertainment 2025-08-23 23:16:52 - browse：25

A DNA helix, with dollar banknotes covering its strands, collapses next to another DNA helix with dollar banknotes strands — coverage from STAT — Adobe

The closely watched gene-editing startup Prime Medicine is embroiled in a multimillion-dollar dispute with another biotech it partnered with to develop a potentially powerful new form of genome editing.

Prime and Myeloid Therapeutics, a startup co-founded by Pulitzer Prize-winning writer and cancer biologist Siddhartha Mukherjee, have filed competing arbitration claims over a deal they signed in March 2022.

Prime, spun out of the lab of Broad Institute biochemist David Liu, was built on technology for making small insertions, deletions, and single-letter changes in DNA. In theory, prime editing allows researchers to tackle the vast majority of disease-causing mutations, and the first treatments are already being readied for clinical trials. But it’s a poor fit in cases where hundreds or even thousands of different mutations in a long gene cause the same diseases, such as cystic fibrosis or Duchenne muscular dystrophy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： How generative AI ratchets up security threats for health systems

entertainment

WSS

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Pancreatic cancer early detection could be helped by AI

Merck drug for rare lung condition set for approval in U.S.

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

How generative AI ratchets up security threats for health systems

hotspot

fashion

entertainment

Jerome Adams on the need for new antivirals for Covid

Why Medicare shouldn’t cover every FDA

United colonoscopy coverage change 'may cost lives,' doctors say

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Activists slam private health insurers over coverage restrictions

Vertex Pharmaceuticals may move headquarters in Boston

As demand for Covid shots wanes, Moderna seeks its next success

Abortion pill case raises question: who can sue the FDA?

At least 13 dead in Texas as scorching temps continue

Covid vaccine financial winners and losers, from Pfizer to Novavax

leisure time

Abortion pill case raises question: who can sue the FDA?

Food as medicine: Medically tailored meals may get standardized

How generative AI ratchets up security threats for health systems

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Scientists boost immune system in aging mice by making it youthful

Steward Health Care has deal to sell doctor network to UnitedHealth

knowledge

explore

entertainment

focus